Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.93 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761163 | 0.96 | SYK (1.00) | SYKMAPK8 | |
| SCHEMBL4419290 | 0.95 | SYK (0.84) | SYKMAPK8MAPK9 | |
| SCHEMBL4419303 | 0.95 | SYK (0.84) | SYKMAPK8MAPK9 | |
| SCHEMBL16204581 | 0.91 | SYK (0.77) | SYKMAPK8MAPK9 | |
| SCHEMBL29865420 | 0.89 | SYK (0.74) | SYK | |
| SCHEMBL760627 | 0.89 | SYK (0.74) | SYK | |
| SCHEMBL735000 | 0.88 | SYK (0.73) | SYKMAPK8MAPK9 | |
| SCHEMBL734999 | 0.88 | SYK (0.73) | SYKMAPK8MAPK9 | |
| SCHEMBL20348692 | 0.87 | SYK (0.84) | SYKMAPK8MAPK9 | |
| SCHEMBL20354305 | 0.85 | SYK (0.81) | SYKMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271631-B1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARM INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150094298-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-04-02 | — | — | US | disclosed |
| US-8937070-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20140031361-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2014-01-30 | — | — | US | disclosed |
| US-20130237493-A1 | COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237493-A1 | COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8501944-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | SYK 1/4885MAPK8 420/4885MAPK9 233/4885 |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | SYK 1/4885MAPK8 497/4885MAPK9 187/4885 |
| US-20130237493-A1 | COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | BCL9, BCL9L, BCL6B | SYK 89/4885MAPK8 1924/4885MAPK9 2370/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | SYK 1/4885MAPK8 497/4885MAPK9 187/4885 |
| US-20140031361-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885MAPK8 420/4885MAPK9 233/4885 |
| US-20150094298-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885MAPK8 420/4885MAPK9 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.